Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements

Rhea-AI Summary

Eagle Pharmaceuticals (OTCMKTS: EGRX) announced on Oct 15, 2025 that its unaudited financial statements for the three and six months ended June 30, 2025 are available for investors.

The statements can be accessed via the company’s investor relations page at https://investor.eagleus.com/events-presentations.

WOODCLIFF LAKE, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three and six months ended June 30, 2025, are available at https://investor.eagleus.com/events-presentations.

About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.

Investor Relations Contact
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

Where can I find Eagle Pharmaceuticals (EGRX) unaudited financial statements for Q2 2025?

The unaudited financial statements for the three and six months ended June 30, 2025 are available at https://investor.eagleus.com/events-presentations.

What periods do Eagle Pharmaceuticals (EGRX) unaudited statements cover in the Oct 15, 2025 announcement?

They cover the three-month and six-month periods ended June 30, 2025.

Are the Eagle Pharmaceuticals (EGRX) June 30, 2025 financial statements audited?

No, the announcement specifies these financial statements are unaudited.

When did Eagle Pharmaceuticals (EGRX) make the unaudited Q2 2025 statements available?

The company announced availability on October 15, 2025.

How can investors review detailed figures from Eagle Pharmaceuticals (EGRX) Q2 2025 filings?

Investors should download the unaudited financial statements posted at https://investor.eagleus.com/events-presentations for detailed figures and notes.